Cork biotech firm secures $300 million funding for budget mRNA vaccine facilities
Normax Biomed is aiming to develop modular vax factories globally. The first one, planned for Cork, will employ around 200 people
Normax Biomed, an Irish-headquartered biotechnology company, has secured a €300 million funding commitment to develop low-cost mRNA vaccines for a wide array of diseases.
The firm plans to open facilities globally. The first will be based in Cork, where it intends to develop a €30 million manufacturing plant that will lead to the creation of 200 jobs.
The financing comes ahead of a planned initial public offering (IPO) with a dual listing on the London ...